UK markets closed

argenx SE (ARGX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
310.18+1.42 (+0.46%)
As of 12:06PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close308.76
Open310.41
Bid309.23 x 800
Ask310.26 x 800
Day's range308.32 - 311.49
52-week range212.66 - 382.15
Volume41,609
Avg. volume164,778
Market cap15.991B
Beta (5Y monthly)0.77
PE ratio (TTM)N/A
EPS (TTM)-6.89
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est342.47
  • Globe Newswire

    argenx Reports Half Year 2021 Financial Results and Provides Second Quarter Business Update

    - Completion of enrollment expected by year-end for ADAPT-SC and ADVANCE (IV) trials of efgartigimod; topline data for both trials expected in first half of 2022 - Introduced “argenx 2025” vision during R&D Day to highlight commitment to patients and science and outline path to becoming global, integrated immunology leader - Management to host conference call today at 2:30 pm CEST (8:30 am ET) - July 29, 2021Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company c

  • Globe Newswire

    argenx to Report Half Year 2021 Financial Results and Second Quarter Business Update on July 29, 2021

    July 22, 2021Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today announced that it will host a conference call and audio webcast on Thursday, July 29, 2021 at 2:30 p.m. CET (8:30 a.m. ET) to discuss its half year 2021 financial results and provide a second quarter business update. A webcast of the live call may be accessed on the Investors section of the argen

  • Globe Newswire

    argenx to Host Virtual R&D Day on July 20, 2021

    July 14, 2021Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today announced that it will host a virtual R&D Day on Tuesday, July 20, 2021 at 3:00 p.m. CET (9:00 a.m. ET) to highlight its ‘argenx 2025 vision’ and provide an update of its immunology pipeline. The event will introduce the fifth and sixth indications for the Company’s FcRn antagonist, efgartigimod,